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Abstract
Background: Sleep restriction, leading to deprivation of sleep, is common in modern 24-h societies and is associated with
the development of health problems including cardiovascular diseases. Our objective was to investigate the immunological
effects of prolonged sleep restriction and subsequent recovery sleep, by simulating a working week and following recovery
weekend in a laboratory environment.
Methods and Findings: After 2 baseline nights of 8 hours time in bed (TIB), 13 healthy young men had only 4 hours TIB per
night for 5 nights, followed by 2 recovery nights with 8 hours TIB. 6 control subjects had 8 hours TIB per night throughout
the experiment. Heart rate, blood pressure, salivary cortisol and serum C-reactive protein (CRP) were measured after the
baseline (BL), sleep restriction (SR) and recovery (REC) period. Peripheral blood mononuclear cells (PBMC) were collected at
these time points, counted and stimulated with PHA. Cell proliferation was analyzed by thymidine incorporation and
cytokine production by ELISA and RT-PCR. CRP was increased after SR (145% of BL; p,0.05), and continued to increase after
REC (231% of BL; p,0.05). Heart rate was increased after REC (108% of BL; p,0.05). The amount of circulating NK-cells
decreased (65% of BL; p,0.005) and the amount of B-cells increased (121% of BL; p,0.005) after SR, but these cell numbers
recovered almost completely during REC. Proliferation of stimulated PBMC increased after SR (233% of BL; p,0.05),
accompanied by increased production of IL-1b (137% of BL; p,0.05), IL-6 (163% of BL; p,0.05) and IL-17 (138% of BL;
p,0.05) at mRNA level. After REC, IL-17 was still increased at the protein level (119% of BL; p,0.05).
Conclusions: 5 nights of sleep restriction increased lymphocyte activation and the production of proinflammatory cytokines
including IL-1b IL-6 and IL-17; they remained elevated after 2 nights of recovery sleep, accompanied by increased heart rate
and serum CRP, 2 important risk factors for cardiovascular diseases. Therefore, long-term sleep restriction may lead to
persistent changes in the immune system and the increased production of IL-17 together with CRP may increase the risk of
developing cardiovascular diseases.
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Introduction
Sleep is generally considered to be a restorative process, having
beneficial effects on immune functions. Partial loss of sleep is
common among people who experience environmental or
psychological stress such as travelling across time zones, having
to do shift work, and in those individuals with psychiatric or
physical disorders. Sleep restriction is becoming increasingly
prevalent, especially among employed middle-aged populations
[1,2]. In modern 24-h societies, increased work demands are a
major cause of chronic deficiency of sleep, leading to increased
amounts of accidents, diseases, and even increased mortality [3]. It
is important to understand the mechanisms by which sleep,
immune responses and health are related if we are to find ways to
manage patients with sleep disorders and people with chronically
restricted sleep.
Sufficient sleep is vital for cardiovascular health and reduced
sleep duration is specifically associated with increased cardiovas-
cular morbidity [4–6]. Many cardiovascular risk factors, including
heart rate, blood pressure and serum CRP concentrations, have
been shown to increase during both short and prolonged periods
of sleep restriction [6]. However, the underlying immunological
mechanisms leading to the development of cardiovascular diseases
remain to be elucidated.
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In the present study, we simulated the accumulation of sleep loss
during five working days followed by two days of weekend
recovery sleep, and measured the changes in immunological
parameters at these time points. We hypothesize that, in addition
to the previously reported adverse effects on cognitive functioning
and metabolism [7,8], continuous sleep restriction disturbs human
immunity which could result in an increased risk of developing
cardiovascular diseases.
Materials and Methods
Participants and study design
Nineteen healthy men, aged 19–29 (mean [SD] age 23.1 [2.5]
years), with a regular sleep-wake schedule and habitual sleep
duration of 7–9 h participated in the study. Physical screening
included blood tests (triglycerides, cholesterol, creatinine, haemo-
globin, haematocrit, MCV, MCH, MCHC, leukocytes, erythro-
cytes, TSH, ASAT, ALAT) and polysomnography (Table S1).
Two weeks prior to the experiment, participants completed sleep
diaries, had an adaptation night in the sleep laboratory and wore
actigraphs in order to verify adherence to a regular sleep-wake
schedule. The pre-study mean (SD) sleep duration was 6.88 (0.58)
h in the control group and 7.05 (0.80) h in the experimental group.
The study design was approved by the ethics committee of
Helsinki University Central Hospital, written informed consent
was obtained from participants, and the experiment was
conducted at the Brain and Work Research Centre of the Finnish
Institute of Occupational Health.
The experimental group (n= 13) spent 8 h in bed for the first
two nights (BL; from 11 PM to 7 AM), followed by 5 nights where
they rested for only 4 h in bed (SR; from 3 AM to 7 AM) and,
finally, again 3 nights of 8 h in bed (REC). The control group
(n = 6) spent 8 h in bed (11 PM to 7 AM) throughout the entire
experiment. Napping during daytime was not allowed and this was
monitored by continuous EEG recordings and a continuously
present investigator. Meals were standardized, provided at fixed
times and finished by all participants throughout the experiment:
breakfast at 8 AM (600 kcal), lunch at 12.30 PM (800 kcal), dinner
at 6 PM (700 kcal); snacks at 3.30 PM (300 kcal) and 9.30 PM
(200 kcal). In addition, participants in the experimental group ate
a piece of fruit at 12.15 AM. Participants were not allowed to leave
the building, but could stay in a living room where there was a
television and a personal computer. Illumination in the sleeping
room and in the test room ranged from 150 to 400 lux, and in the
living room from 350 to 600 lux. The temperature ranged from 19
to 23uC.
High sensitivity C-reactive protein (hs-CRP) and cortisol
assays
Blood samples were taken from participants at 7.30 AM and
analyzed by Medix Laboratories, Espoo, Finland for high
sensitivity C-reactive protein (hs-CRP) using immunoturbidimetry.
Morning peak values of cortisol were assessed using saliva samples
that were collected 10 times a day and their cortisol levels were
measured using a commercial kit assay (Salivary Cortisol, LIA,
IBL, Hamburg, Germany). The measurement range was 0.43–
110 nmol/L with assay repeatability values of 5% (within series)
and 8% (between series).
Heart rate and blood pressure measurements
ECG- based (WinAcq, AbsoluteAliens, Finland) heart rate
together with continuous systolic and diastolic blood pressure
(Portapres, Finapres Medical Systems, the Netherlands) was
measured between 8 AM and 9 AM during a 10 minute period
of rest.
Peripheral blood mononuclear cells and flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized venous blood by density gradient centrifugation as
earlier described [9]. Cell distribution of PBMC was then assessed
by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA,
USA) using FACSComp software version 4.01 (BD Biosciences)
[9]. Briefly, PBMC were incubated with (phycoerythrin-Cy5 (PE-
Cy5)-conjugated anti-CD3 or with PE-conjugated anti-CD4, anti-
CD56, anti-CD19, or with fluorescein isothiocyanate (FITC)-
conjugated anti-CD8 or anti-CD14, and the corresponding isotype
controls, which were all obtained from BD Biosciences. After
incubation with monoclonal antibodies, cells were washed, and
fixed in 1% paraformaldehyde (BD Biosciences). A total of 10000
events within the lymphocyte and monocyte gates was collected.
The number of CD14+ cells (monocytes) within the monocyte gate
and CD3+ (T cells), CD3+CD4+ (T helper cells), CD3+CD8+
(cytotoxic T cells), CD3-CD56+ (natural killer cells, NK cells) and
CD19+ cells (B cells) within the lymphocyte population were
analyzed by BD CELLQuestPro software (BD Biosciences).
Proliferation assay of PBMC
Isolated PBMC were washed twice with phosphate buffered
saline (PBS) and proliferation of PBMC was performed in
complete RPMI 1640 containing 5% heat-inactivated human
AB serum on 96-well U-bottomed plates (Costar Corning
Incorporated, Corning, NY, USA) as earlier described [9]. Briefly,
PBMC were cultured in triplicate (105 cells/200 mL/well) alone or
together with phytohaemagglutinin (PHA, 45 mg/mL; Murex
Biotech Ltd, Dartford, UK). After 3 days of culture, tritiated
methyl-thymidine ([methyl-3H]-TdR, Amersham Biosciences,
Little Chalfont, UK) was added for 24 h. The results were
calculated as stimulation indexes (uptake of isotype in stimulated
culture/uptake of isotype in non-stimulated medium control
culture) and expressed as percentages of individual baseline levels.
Cytokine assays
Separated and washed PBMC were stimulated with PHA
(45 mg/mL) in complete RPMI 1640 medium on 24-well plates
(Costar) (36106 cells/1.5 mL/well). The total number of cells per
stimulation was 66106. Cell pellets were collected after 6 h of
incubation and used for RNA isolation. Cell culture supernatants
were obtained after 24 h of incubation and stored at 270uC
before measurement of cytokine protein levels.
Total RNA isolation, synthesis of cDNA and real-time
quantitative PCR with an AbiPrism 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA) were
performed as described earlier [9]. Primers and probes for PCR
were designed and purchased from Applied Biosystems. The
results were calculated by the comparative CT method according
to the instructions of Applied Biosystems using ribosomal 18 S as
an endogenous control.
Cytokine protein analysis was made with the Luminex bead
system (Bio-Plex 200 System, Bio-Rad Laboratories, Hercules,
CA, USA) by labelled cytokine capture antibody pairs (Bio-Rad
Laboratories).
Statistical analysis
Data were expressed as percentages of each individual
participant’s baseline values unless otherwise specified. We have
compared sleep restriction and recovery values to baseline values
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by applying paired t-tests for normally distributed differences and
Wilcoxon signed ranks tests for differences that were not normally
distributed. The normality of differences was checked using
Kolmogorov-Smirnov goodness of fit test. A P value,.05 was
considered to be statistically significant. All statistical analyses were
carried out using SPSS version 15 (SPSS Inc., Chicago, USA).
Results
Cell distribution of PBMC
The cell distribution of peripheral blood describes the general
immune status of these individuals. The total number of T cells
(Figure 1) as well as the numbers of helper T-cells and cytotoxic T-
cells did not change throughout the experiment either in the
experimental or in the control group (Table S2). The number of
NK-cells decreased significantly after the period of sleep restriction
(to 65% of baseline levels, p,0.005), returning back to baseline
levels after recovery (89% of baseline levels; Figure 1). The
number of B cells increased significantly after the period of sleep
restriction (to 121% of baseline levels, p,0.005) and returned to
baseline levels again after recovery (111% of baseline levels;
Figure 1). In the control group, the number of B-cells and NK-cells
did not change throughout the experiment (Figure 1).
CRP, Heart rate, blood pressure, and cortisol
C-reactive protein (CRP) is an important risk factor for many
diseases, including stroke and hypertension [10,11]. Serum CRP
increased significantly after sleep restriction (145% [p,0.05] of
baseline levels) with the elevation being even more pronounced
after recovery sleep (231% [p,0.05] of baseline levels; Figure 2).
Figure 1. Cell distribution of PBMC. Number of T cells, B cells, and natural killer (NK) cells in PBMC, expressed as percentage of participant’s
individual baseline values. SR = sleep restriction, REC= recovery, Con= control group, Exp = sleep restriction group. Data are presented as mean
values 6SEM. * p,0.05.
doi:10.1371/journal.pone.0004589.g001
Figure 2. PBMC proliferation and hs-CRP. Proliferation of PBMC after stimulation with phytohaemagglutinin (PHA, 45 mg/mL) and high
sensitivity C-reactive protein (hs-CRP) concentrations in plasma. SR = sleep restriction, REC= recovery, Con= control group, Exp = sleep restriction
group. Data are expressed as percentages of participant’s individual baseline values (mean6SEM). * p,0.05.
doi:10.1371/journal.pone.0004589.g002
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Heart rate increased throughout the experiment, reaching
significance after recovery (108% [p,0.05] of baseline levels;
Table S2). On the other hand, concentrations of stress hormone
cortisol were not changed after sleep restriction (Table S2). Blood
pressure values remained unaffected throughout the entire study
(Table S2). In the control group, CRP, heart rate, cortisol, and
blood pressure did not change during the experiment (Table S2).
Proliferation of activated PBMC
Proliferation of PHA activated PBMC reflects the immunolog-
ical capability of peripheral blood cells. Proliferation of PBMC in
the experimental group was significantly increased after sleep
restriction compared to baseline (to 233% [p,0.05] of baseline
levels; Figure 2). After recovery sleep, there was still a tendency
towards increased proliferation (341% [p=0.53] of baseline levels).
In contrast, cell proliferation in the control group decreased to
81% (p,0.05) and 90% (p=0.35) of baseline levels, respectively
(Figure 2).
Cytokine production of PHA activated PBMC
Cytokine profiles of activated PBMC reflect the dominating
immune responses. The amounts of proinflammatory cytokines IL-
1b and IL-6 increased significantly at the mRNA level (to 137%
[p,0.05] and 163% [p,0.05] of baseline levels, respectively)
whereas TNF-a decreased at the protein level after sleep restriction
(to 80% [p,0.05] of baseline levels; Figure 3). After recovery sleep,
concentrations of IL-6, IL-1b and TNF-a did not return to baseline
levels completely. IL-17 showed significantly increased expression at
mRNA level after sleep restriction (138% [p,0.05] of baseline
levels) and at protein level after subsequent recovery sleep (119%
[p,0.05] of baseline levels). The mRNA expression of all cytokines
in the control group remained at the baseline level at all timepoints.
Discussion
Chronic sleep deprivation is becoming increasingly common in
modern, 24-h societies due to voluntary sleep restriction and
increasing work demands [1,2]. Sleep loss results in tiredness and
impaired cognitive performance [8], but it also affects immune
functions, leading to an increased number of infections [12,13].
Moreover, it has been shown both epidemiologically and
experimentally that reduced sleep duration is associated with an
increased risk of developing diabetes [14], obesity [15], and
cardiovascular diseases [4–6]. An accelerated heart rate is a sign of
stress in the cardiovascular system [16]. In the present study, heart
rate was significantly increased at the end of the experiment. This
could be viewed as an alarm reaction in the circulatory system that
might, at least partially, be a consequence of reduced parasym-
pathetic tone and/or increased sympathetic tone in the autonomic
Figure 3. Cytokine mRNA and protein expression. Cytokine mRNA and protein expression of phytohaemagglutinin (PHA, 45 mg/mL) activated
PBMC. SR = sleep restriction, REC= recovery, Con= control group, Exp= sleep restriction group. Data are expressed as percentages of participant’s
individual baseline values (mean6SEM). * p,0.05.
doi:10.1371/journal.pone.0004589.g003
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nervous system (ANS). Serum cortisol and blood pressure
remained unaffected throughout the current experiment, probably
due to the fact that chronic changes in those parameters require
more time to develop. Indeed, it has been shown that a more
extended period of six nights of sleep restricted to 4 h per night
results in elevated evening cortisol concentrations [17].
NK cells are phagocytes of innate immunity that quickly
recognize, engulf and destroy intracellular pathogens whereas T
cells and B cells orchestrate adaptive immunity through cellular
and humoral responses. We observed a decrease in NK cell
numbers as well as an increase in the number of B cells after five
nights of sleep restriction. On the other hand, there were no
changes in the number of T cells or their CD4+ and CD8+
subtypes. Sleep deprivation as well as stress factors have been
shown to decrease the number and function of NK cells, often
associated with increased susceptibility to infections [18,19]. It
should be noted, however, that the number of both NK cells and
B-cells returned to baseline level during the two nights of recovery
sleep in the present study. This suggests that the differences in the
numbers of these cells in the circulation are probably due to
reversible redistribution of these cells between lymphoid organs
and periphery. In addition to cell numbers, the function of the
immune cells plays a key role in successful immunity.
In our study, peripheral T cells showed highly elevated
proliferation responses to PHA. This suggests that T cells in sleep
deprived people, compared to people with normal sleep, are
primed and after non-specific stimulation they respond more
efficiently. A similar effect was observed in a recent study where
stressed mice survived as well as or even better than non-stressed
mice during a primary pneumococcus infection, but their survival
was strongly reduced during secondary infection [20]. This was
assumed to be due to a temporary immune-enhancing effect that
later converted to a diminished adaptive immune response. In
more extreme cases, chronic sleep loss in rats has resulted in severe
inflammation in body tissues, culminating in lethal bacterial
invasion of the bloodstream [21]. Therefore, over-activation of
effector cells may enhance immunity and help the individual to
survive through extraordinary conditions in the short term, but
prolonging this situation leads to inflammation, and tissue injury.
CRP is widely used as a general marker for inflammation [10].
In the present study, serum hs-CRP concentrations were elevated
immediately after sleep restriction and, since this peptide has an in
vivo half life of 19 h [22], this elevation sustained after two days of
recovery sleep. Similarly, a previous study has shown that both
total (88 hours) as well as partial (4.2 hours during 10 consecutive
nights) sleep restriction significantly increased serum concentra-
tions of hs-CRP [6]. Elevated serum CRP is a risk factor for
cardiovascular diseases and predicts future cardiovascular events
and even mortality in apparently healthy people [10,23]. CRP co-
localizes with modified low density lipoprotein (LDL) in human
atherosclerotic plaques, and it has been shown to increase platelet
adhesion to endothelial cells. Therefore, in addition to acting as a
biomarker, CRP plays a causal role in the development of
atherosclerosis and thrombosis [11]. Animal studies also support
the proinflammatory and pro-atherogenic role of CRP, because
administration of human CRP or over-expression of CRP in
apolipoprotein E -deficient mice promotes the development of
spontaneous atherosclerosis [24]. Previously it has been reported
that synthesis of CRP in the liver is controlled by proinflammatory
cytokines, including IL-6, TNF-a and IL-1 [25]. In our study, the
production of IL-6 and IL-1b was clearly increased by PHA
activation of PBMC after sleep restriction and remained elevated
after recovery sleep, whereas the production of TNF-a was slightly
reduced, but recovered after two days of recovery sleep. Cytokines
IL-1 and IL-6 play a crucial role in immune defenses and their
secretion also regulates sleep-wake rhythms and sleep patterns,
respectively [26]. In line with the results of our study, it was
recently shown that IL-6 increased during prolonged sleep
restriction when subjects slept only 4 hours per night for 12 days
[27]. Independently of high cholesterol or myocardial damage
markers, IL-6 predicts future adverse cardiovascular events and
reflects increased inflammatory activity in plaques and is therefore
a strong marker of increased risk for mortality in coronary artery
diseases [28,29]. IL-1b is a proinflammatory cytokine; the
processing of its inactive form (pro-IL-1b) to the active form is
triggered by microbial products and metabolic stress, leading to
increased lymphocyte activation and destruction of local tissues.
Thus, secretion of biologically active IL-1b protein may be
induced when sleep deprived people are infected (i.e. enhanced
susceptibility to viral and bacterial infections), a phenomenon
which is frequently associated with chronic sleep deprivation.
In the present study, five days of sleep restriction were
associated with increased IL-17 production both at the mRNA
and the protein levels from PHA activated PBMC, and the
amount of IL-17 remained elevated after the recovery period. IL-
17 is a relatively newly-discovered member of the proinflamma-
tory cytokines. It plays a key role in sustaining tissue damage in
several tissues such as brain, joints, heart, lung and intestine,
sometimes promoting the development of autoimmune diseases
[30]. Inflammation is an important component in all stages of
atherosclerosis and interestingly, IL-17 has recently been reported
to stimulate expression of CRP in hepatocytes and in coronary
artery smooth muscle cells [31]. On the basis of these results, we
propose a hypothesis for the sleep restriction-induced development
of cardiovascular diseases (Figure 4). Prolonged sleep restriction
results in activation of the synthesis of proinflammatory cytokines
IL-1b and IL-6 which in turn increases the expression of IL-17.
These cytokines play an important role in the induction of CRP
which may facilitate, directly or indirectly, the formation of
atherosclerotic plaques leading to an increased risk for cardiovas-
cular diseases. This detrimental pathway may be even further
activated by simultaneous exposure to a microbial infection.
However, understanding of the mechanisms of IL-17 in bridging
innate and adaptive immunity is still in its infancy, and therefore
the specific role of IL-17 in the development of cardiovascular
diseases needs to be studied in more detail.
In conclusion, we identified how prolonged sleep restriction can
change immune cell functions, and may lead to an increased risk
to develop cardiovascular diseases. Several immunological changes
that occurred after five days of sleep restriction did recover after
two nights of normal sleep, but the elevated level of serum hs-CRP
that was accompanied by increased production of proinflamma-
tory cytokines, especially IL-17, did not return to normal. In
summary, these results indicate that immunological changes that
take place after multiple nights of short sleep cannot be restored
completely by sleeping normally for a few nights, and long-term
sleep restriction may lead to an increased risk of developing
cardiovascular diseases.
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